Ischemic optic neuropathy (ION) is a sudden loss of vision caused by reduced blood flow to the optic nerve, the cable that carries visual signals from your eye to your brain. It is the most common cause of acute optic nerve damage in adults over 50, affecting roughly 2 to 10 people per 100,000 each year. The vision loss is typically painless, often noticed first thing in the morning, and can range from partial blurring in one eye to near-complete blindness.
How Blood Flow Disruption Damages the Nerve
Your optic nerve depends on a network of tiny arteries branching off a larger vessel called the ophthalmic artery. These small branches, known as the posterior ciliary arteries, deliver oxygen to the front portion of the nerve where it connects to the eye. When blood flow through these arteries drops below a critical threshold, nerve fibers begin to swell and die. Unlike a stroke in the brain, where a clot often blocks a single vessel, most cases of ischemic optic neuropathy involve a more general drop in perfusion pressure rather than a single blockage. The swelling that follows the initial injury can compress neighboring nerve fibers, sometimes worsening the damage over the first few days.
Two Main Types: Non-Arteritic and Arteritic
Ischemic optic neuropathy falls into two major categories, and distinguishing between them matters because one is a medical emergency.
Non-Arteritic (NAION)
NAION accounts for the vast majority of cases. It strikes when blood flow to the optic nerve head dips too low, often overnight when blood pressure naturally falls. Most people notice the vision loss upon waking, either from a full night’s sleep or even a nap. The loss is painless and typically affects the lower half of the visual field in one eye, though other patterns occur. In some people, vision worsens gradually over about two weeks rather than appearing all at once.
A key structural risk factor is having a small, tightly packed optic disc, sometimes called a “disc at risk.” Up to 97% of NAION patients have this anatomical feature, where the opening through which blood vessels enter the eye is unusually small (a cup-to-disc ratio of 0.2 or less). This crowding leaves little room for swelling, so even a modest drop in blood flow can trigger a cascade of damage. You can’t change your disc anatomy, but it helps explain why NAION happens to some people and not others with the same cardiovascular risk profile.
Arteritic (AION)
Arteritic ischemic optic neuropathy is caused by giant cell arteritis, an inflammatory disease that attacks medium and large arteries, particularly those supplying the head and eyes. The inflammation narrows or blocks the arteries feeding the optic nerve, often causing more severe and sudden vision loss than NAION. Blurring, darkening, dimming, or complete loss of vision can develop over minutes to hours.
What makes AION an emergency is that without treatment, the second eye is at high risk. Giant cell arteritis also produces systemic warning signs: new-onset headaches, tenderness along the temples, jaw pain that worsens with chewing, muscle aches, fatigue, and sometimes double vision. Jaw pain during chewing and double vision are the two most diagnostically powerful indicators of the condition. If blood tests show elevated inflammatory markers, a biopsy of the temporal artery confirms the diagnosis, and treatment with high-dose steroids begins immediately to protect the remaining vision.
Posterior Ischemic Optic Neuropathy
A less common third category, posterior ischemic optic neuropathy (PION), affects the portion of the optic nerve behind the eyeball rather than the front. It tends to worsen progressively in its early phase and is most often seen after major surgeries, particularly long spinal procedures where blood pressure drops for extended periods.
Risk Factors That Increase Your Odds
NAION shares many risk factors with cardiovascular disease: high blood pressure, diabetes, smoking, and atherosclerosis all contribute. But a few risk factors are more specific to this condition.
Obstructive sleep apnea carries a more than six-fold increased risk of NAION compared with people who don’t have the condition. The repeated drops in oxygen and blood pressure during apnea episodes are thought to starve the optic nerve overnight, which aligns with the common pattern of waking up with vision loss. If you have untreated sleep apnea and other cardiovascular risk factors, this is worth discussing with your doctor.
Nocturnal blood pressure drops matter as well. People who already take blood pressure medication may experience exaggerated dips during sleep, reducing perfusion to an optic nerve that is already anatomically crowded. Age is another major factor; NAION rarely occurs before 50.
What the Vision Loss Looks Like
The classic pattern in NAION is an inferior altitudinal defect, meaning you lose the bottom half of your vision in one eye as though a curtain has been pulled up from below. Other patterns include loss of the lower-inside portion of your visual field, a dark spot near the center, or arc-shaped blind areas. Central vision (the sharpness you use for reading) may or may not be affected, depending on which nerve fibers are damaged.
In arteritic cases, the vision loss tends to be more severe. Complete or near-complete loss of vision in the affected eye is more common than with NAION, and the onset can be preceded by brief episodes of transient vision loss (lasting seconds to minutes) in the days or weeks before the permanent event.
How It’s Diagnosed
An eye doctor can often diagnose ischemic optic neuropathy by examining the back of the eye. In the acute phase of anterior ION, the optic disc appears swollen, sometimes with small hemorrhages at its border. The pattern of swelling, the visual field loss, and the patient’s age and risk factors usually point clearly to the diagnosis.
The critical next step is determining whether the cause is arteritic or non-arteritic. Blood tests measuring inflammation (the sedimentation rate and C-reactive protein) are drawn urgently. An elevated sedimentation rate above 50 mm/h raises suspicion for giant cell arteritis. If the clinical picture fits, a temporal artery biopsy is performed to confirm the diagnosis, often the same day, because treatment cannot wait.
Treatment and Recovery
The two types follow very different treatment paths.
Arteritic ION
Giant cell arteritis requires immediate high-dose steroids to reduce inflammation and protect the other eye. Treatment typically starts with oral steroids and is tapered gradually over many months, guided by regular blood tests and symptom monitoring. Some cases require intravenous steroids initially. The taper is slow and carefully managed because flare-ups can occur if the dose drops too quickly. Most patients remain on some level of steroid therapy for one to two years. Prompt treatment can prevent vision loss in the second eye, which is why recognizing the systemic symptoms (headache, jaw pain, scalp tenderness) is so important.
Non-Arteritic ION
NAION has no proven treatment. Multiple interventions have been studied over the decades, including steroids, blood thinners, and surgical decompression of the optic nerve sheath, but none has shown consistent benefit. The vision loss from NAION tends to stabilize within a few weeks. Some patients experience modest spontaneous improvement over the following months, though significant recovery is uncommon. The visual field loss that remains after the acute phase is generally permanent.
Management focuses on reducing the risk of a future episode in the other eye. That means addressing the modifiable cardiovascular risk factors: controlling blood pressure and blood sugar, treating sleep apnea if present, and stopping smoking. If you take blood pressure medication, your doctor may review whether the timing of your dose could be contributing to excessive overnight drops.
Risk of the Second Eye
One of the most common concerns after a first episode of NAION is whether the other eye will be affected. The cumulative risk of the fellow eye developing NAION over the following five years is estimated at roughly 15 to 20%. Having a small optic disc in the unaffected eye (which is usually the case, since disc anatomy tends to be symmetrical) is the primary structural vulnerability. Controlling vascular risk factors is the best available strategy for reducing that risk, though it cannot eliminate it entirely.